Alexion Pharmaceuticals Inc. — Sponsor Intelligence | 29 EU Trials

Filter these 29 trials by condition, phase, country and more.

Open in Search →

29 Registered trials

12 Recruiting

15 Completed trials

21 Countries active

30 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 19 Phase II/III: 1 Phase II: 7 Phase IV: 1 Phase I (FiH): 1

Oversight events:

1 serious breach 10 temporary halts 3 corrective measures across 5 trials

View oversight register →

100%

15 of 15 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Lupus nephritis 2 Cardiac amyloidosis 2 IgA nephropathy 2 Paroxysmal nocturnal haemoglobinuria 1 Acromegaly 1 Hypophosphatasia 1 Neuromyelitis optica spectrum disorder 1 Hypoparathyroidism 1 Familial dilated cardiomyopathy 1 Thrombotic microangiopathy 1

Top IMPs

RAVULIZUMAB 11 ALXN1850 3 DANICOPAN 3 ANSELAMIMAB 2 GEFURULIMAB 2 [ALA1,3,12,GLN10,ARG11,TRP14]PTH(1-14)/[ALA18,22, LYS26]PTHRP(15-36)COOH 1 AAV9-CTNT-COBAG3 1 ALFACALCIDOL 1 ALXN1920 1 ALXN2220 1 ALXN2420 1 ASFOTASE ALFA 1

All trials

29 total

Phase 3 Study of ALXN1850 in Pediatric Participants with HPP Previously Treated with Asfotase Alfa Revoked

2023-505674-15-00 Phase III 3 countries ALXN1850; ASFOTASE ALFA
A Phase 1/2 study of ALXN2350 in adult participants with BAG3-associated dilated cardiomyopathy Recruiting

2024-519674-40-00 Phase I (FiH) 3 countries AAV9-CTNT-COBAG3; PREDNISONE; SIROLIMUS; SULFAMETHOXAZOLE, TRIMETHOPRIM
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants with HPP Recruiting

2023-505675-73-00 Phase III 8 countries ALXN1850
Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Recruiting

2022-503126-12-01 Phase III 10 countries [ALA1,3,12,GLN10,ARG11,TRP14]PTH(1-14)/[ALA18,22, LYS26]PTHRP(15-36)COOH; ALFACA…
A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicit… Recruiting

2022-501882-29-00 Phase III 4 countries RAVULIZUMAB
A study to determine if ALXN2030 is effective and safe in adults with antibody-mediated rejection after kidney transplantation (CONCORD) Recruiting

2024-517498-25-00 Phase II 1 country RNA, (AM-SP-UM-CM-AM-AM-CM-UM-(2'-DEOXY-2'-FLUORO)C-(2'-DEOXY-2'-FLUORO)A-(2'-DE…
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients with AChR+ Generalized Myasthenia Gravis Recruiting

2024-515157-17-00 Phase III 1 country GEFURULIMAB
Phase 2a Study of ALXN1920 in PMN Recruiting

2025-520780-40-00 Phase II 3 countries ALXN1920
Safety and Efficacy of Tarperprumig in Adult Participants with ANCA-Associated Vasculitis Recruiting

2025-521706-17-00 Phase II 5 countries TARPERPRUMIG
Phase 3 Study of Ravulizumab versus Placebo in Adult Participants at High Risk of DGF after Kidney Transplantation (AWAKE) Recruiting

2024-517568-48-00 Phase III 8 countries RAVULIZUMAB
A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatri… Recruiting

2024-520167-13-00 Phase III 2 countries RAVULIZUMAB
An Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants with PNH Who Have Clinically Sig… Recruiting

2024-511795-32-00 Phase III 1 country DANICOPAN
Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD Recruiting

2023-508534-33-00 Phase II/III 3 countries RAVULIZUMAB
A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended

2023-507851-31-00 Phase III 12 countries RAVULIZUMAB
Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al… Ended

2023-505673-32-00 Phase III 8 countries ALXN1850
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended

2023-506669-70-00 Phase III 14 countries ALXN2220
A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended

2023-504867-18-00 Phase III 6 countries DANICOPAN; ECULIZUMAB; RAVULIZUMAB
Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended

2023-508284-77-00 Phase III 9 countries GEFURULIMAB
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended

2022-503072-84-00 Phase III 8 countries ANSELAMIMAB
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended

2022-503073-11-00 Phase III 9 countries ANSELAMIMAB
Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly Halted

2025-521243-20-00 Phase II 7 countries ALXN2420
ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended

2022-501802-36-00 Phase III 8 countries RAVULIZUMAB
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended

2023-508571-37-00 Phase II 8 countries DANICOPAN
Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended

2023-504825-38-00 Phase II 3 countries VEMIRCOPAN

Showing 1–24 of 29 trials

← All sponsors A–Z